Kymera Therapeutics (KYMR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.62
- Estimate
- -$0.74
- Surprise
- +16.0%
- Revenue (period 2026-06-30)
- $65.0M
- Score today
- 4.6/10
Revenue source: xbrl.
How the report landed
Kymera Therapeutics (KYMR) reported a narrower loss than forecast — adjusted EPS of -$0.62 against the -$0.74 estimate (a 16.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates KYMR Sell at 4.6/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +16.0% surprise compares with a -3.6% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Target reached (-0.1% upside)
- Quality below floor (2.5 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $126.00
- Stop
- $117.18
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
KYMR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.19B
- P/E (fwd)
- -24.0
- 52-week range
- $55.66–$130.05
- Off 52-week high
- 3.1%
- RSI (14)
- 68
- Volume vs avg
- 0.04×
- Score today
- 4.6/10